AUPH Aurinia Pharmaceuticals (AUPH) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001600620
C-suite buying · 1Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
154
13F, latest reported quarter
What the filings say about AUPH
Insiders, 180 days
+$11.9M net bought
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$719.1K
1 notice
Aurinia Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Aurinia Pharmaceuticals Inc. insiders bought a net $11.9M of stock across 111 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Aug 21, 2026.
- The trade is 2.0% of the 588,848 shares held after it.
- No other insider sold within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Robertson Stephen P. sold about $190.4K of AUPH on Sep 10, 2026; 154 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Mar 4, 2025.
- The trade is 3.5% of the 600,787 shares held after it.
- No other insider sold within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Robertson Stephen P. sold about $355.9K of AUPH on Aug 21, 2026, the largest insider sale at the company since 2025; 154 funds added in the latest 13F quarter.Context
- 22 earlier Form 4 trades (code P or S) here by this insider (22 buys), the last on Jun 1, 2026.
- +6.3% median (+4.1% mean) 90-day return after 14 previous buys.
- The trade is 1.6% of the 13,044,106 shares held after it.
- No other insider bought within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer TANG KEVIN bought about $3.1M of AUPH on Jun 2, 2026; 154 funds added in the latest 13F quarter.Context
- 20 earlier Form 4 trades (code P or S) here by this insider (20 buys), the last on May 29, 2026.
- +7.5% median (+4.0% mean) 90-day return after 13 previous buys.
- The trade is 2.7% of the 12,838,002 shares held after it.
- No other insider bought within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer TANG KEVIN bought about $5.2M of AUPH on Jun 1, 2026; 154 funds added in the latest 13F quarter.Context
- 20 earlier Form 4 trades (code P or S) here by this insider (20 buys), the last on May 29, 2026.
- +7.5% median (+4.0% mean) 90-day return after 13 previous buys.
- The trade is 0.0% of the 12,838,101 shares held after it.
- No other insider bought within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer TANG KEVIN bought about $1.5K of AUPH on Jun 1, 2026; 154 funds added in the latest 13F quarter.111 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$11.9M over 180 days
-$546.4K over 90 days · +$12.5M of it by a 10%+ holder
more than 96% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
154 funds bought in last quarter
more than 83% of Pharma & Biotech
Revenue
+20.4% year over year
more than 67% of Pharma & Biotech
Margin
101.5% net margin
more than 98% of Pharma & Biotech
Buybacks
$74.9M repurchased, FY to 2026-06-30
more than 64% of Pharma & Biotech
Short interest
6.1% of the float short (float per yahoo 2026-10-26) · 9.4 days to cover · settled 2026-09-30
more than 56% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 5 in the prior 90
Why it matters
The absence is the signal: 5 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch AUPH
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+49.0%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns AUPH: institutional holders (13F)
13F holdings, latest reported quarter
13,044,106 sh
$221.4M
8,193,085 sh
$139.0M
5,619,401 sh
$95.4M
3,969,834 sh
$67.4M
3,467,514 sh
$58.8M
Congress trades in AUPH
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
AUPH planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Stephen P. Robertson
Filed 2026-08-21
$719.1K
AUPH mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Etf
$1.3M position · as of 2026-07-31
1.3%
HUSSMAN STRATEGIC MARKET CYCLE FUND
$3.4M position · as of 2026-06-30
1.0%
DIAMOND HILL INTERNATIONAL FUND
$1.6M position · as of 2026-06-30
0.9%
HUSSMAN STRATEGIC ALLOCATION FUND
$169.7K position · as of 2026-06-30
0.7%
NVIT GS Small Cap Equity Insights Fund
$1.1M position · as of 2026-06-30
0.5%
Goldman Sachs Small Cap Growth Insights Fund
$1.7M position · as of 2026-07-31
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
4
Phase 3
0 active
1
Phase 4
1 active
1
Not applicable
0 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Peter Greenleaf
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$5.9M
$17.6M
$2.1M
+15%
-16%
2024
$6.4M
$7.6M
$2.2M
-35%
-37%
2023
$10.6M
$14.9M
$3.9M
-35%
-31%
2022
$8.8M
-$8.9M
$3.3M
-69%
-30%
2021
$1.2M
$16.3M
$718.2K
+65%
-8%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $11.9M bought by insiders over 180 days, 154 funds added last quarter, $719.1K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
AUPH financials
Revenue growth
+20.4%
XBRL, annual
Net margin
101.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$311.5M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM AUPH
| FY Dec 2025 | $283.1M |
| FY Dec 2024 | $235.1M |
| FY Dec 2023 | $175.5M |
| FY Dec 2022 | $134.0M |
| FY Dec 2021 | $45.6M |
| Jun 2026 | $83.2M |
| Mar 2026 | $77.7M |
| Dec 2025 | $77.1M |
| Sep 2025 | $73.5M |
| Jun 2025 | $70.0M |
| Mar 2025 | $62.5M |
| Dec 2024 | $59.9M |
| Sep 2024 | $67.8M |
At each fiscal year end
Single quarter
Net margin, TTM
+100.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM AUPH
| FY Dec 2025 | +101.5% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -44.5% |
| FY Dec 2022 | -80.7% |
| FY Dec 2021 | -396.8% |
| Jun 2026 | +45.0% |
| Mar 2026 | +44.2% |
| Dec 2025 | +273.4% |
| Sep 2025 | +42.9% |
| Jun 2025 | +30.7% |
| Mar 2025 | +37.4% |
| Dec 2024 | +2.4% |
| Sep 2024 | +21.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$175.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM AUPH
| FY Dec 2025 | $135.4M |
| FY Dec 2024 | $44.1M |
| FY Dec 2023 | -$34.2M |
| FY Dec 2022 | -$79.8M |
| FY Dec 2021 | -$158.0M |
| Jun 2026 | $52.6M |
| Mar 2026 | $32.5M |
| Dec 2025 | $45.6M |
| Sep 2025 | $44.4M |
| Jun 2025 | $44.1M |
| Mar 2025 | $1.3M |
| Dec 2024 | $30.1M |
| Sep 2024 | $16.9M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity AUPH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt AUPH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+66.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity AUPH
| FY Dec 2025 | +59.9% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -19.9% |
| FY Dec 2022 | -24.5% |
| FY Dec 2021 | -40.8% |
| Jun 2026 | +66.1% |
| Mar 2026 | +65.0% |
| Dec 2025 | +59.9% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -5.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+48.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets AUPH
| FY Dec 2025 | +44.1% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -15.3% |
| FY Dec 2022 | -21.3% |
| FY Dec 2021 | -35.9% |
| Jun 2026 | +48.5% |
| Mar 2026 | +48.5% |
| Dec 2025 | +44.1% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -4.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
effective tax rate -96%, not meaningful
Return on invested capital AUPH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+27.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed AUPH
| FY Dec 2025 | +18.9% |
| FY Dec 2024 | -1.0% |
| FY Dec 2023 | -20.5% |
| FY Dec 2022 | -24.0% |
| FY Dec 2021 | -38.7% |
| Jun 2026 | +27.0% |
| Mar 2026 | +23.2% |
| Dec 2025 | +18.9% |
| Sep 2025 | +15.2% |
| Jun 2025 | +11.9% |
| Mar 2025 | +6.9% |
| Dec 2024 | -1.0% |
| Sep 2024 | -6.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
7.53x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing AUPH
| FY Dec 2025 | 7.67x |
| FY Dec 2024 | 179.60x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 7.41x |
| Mar 2026 | 6.83x |
| Dec 2025 | 7.67x |
| Sep 2025 | 19.73x |
| Jun 2025 | 19.70x |
| Mar 2025 | 28.71x |
| Dec 2024 | 179.60x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value AUPH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+7.6%
TTM free cash flow over market value at close 2026-10-27
FCF yield AUPH
| FY Dec 2025 | +6.4% |
| FY Dec 2024 | +3.4% |
| FY Dec 2023 | -2.6% |
| FY Dec 2022 | -13.0% |
| FY Dec 2021 | -5.3% |
| Jun 2026 | +8.0% |
| Mar 2026 | +8.5% |
| Dec 2025 | +6.4% |
| Sep 2025 | +8.2% |
| Jun 2025 | +8.1% |
| Mar 2025 | +5.8% |
| Dec 2024 | +3.4% |
| Sep 2024 | +2.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.02x
P/E over trailing EPS growth of 433%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing AUPH
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.02x |
| Mar 2026 | 0.01x |
| Dec 2025 | 0.00x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $283.1M | $235.1M | $175.5M | $134.0M |
| Operating income | $104.9M | -$4.7M | -$91.7M | -$111.5M |
| Net income | $287.2M | $5.8M | -$78.0M | -$108.2M |
| EPS (diluted) | 2.07 | 0.04 | -0.54 | -0.76 |
| Operating cash flow | $135.7M | $44.4M | -$33.5M | -$79.5M |
| Cash | $80.2M | $83.4M | $48.8M | $94.1M |
| Buybacks | $98.2M | $40.2M | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
AUPH Stock Sonar score 5/7 axes
Find similar shapesCompareAUPH ranks highest on profitability (96th percentile) and institutional and government (83rd), and lowest on risk and compliance (53rd), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
AUPH filings, in plain words
Are Aurinia Pharmaceuticals insiders buying or selling AUPH?
In the 180 days to 2026-10-28, Aurinia Pharmaceuticals insiders were net buyers, a net $11.9M: $12.5M of purchases and $546.4K of sales reported on Form 4, by 1 buyer and 1 seller.
Are there planned insider sales of AUPH?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $719.1K of stock; the latest, by Stephen P. Robertson, was filed 2026-08-21.
Read the full summary
In the 180 days to 2026-10-28, Aurinia Pharmaceuticals insiders were net buyers of AUPH, a net $11.9M across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Most of that figure, $12.5M, came from a holder of 10% or more rather than an officer or director. Purchases outweighed sales more than tenfold by value. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $719.1K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
